Zhejiang Hisun Pharma was chosen to be the commercial supplier of ThermoDox®, a clinical-stage liver cancer drug developed by Celsion of the US. ThermoDox® is Celsion's proprietary liposomal encapsulation of doxorubicin. Hisun positioned the agreement as a step toward developing a portfolio of branded generics products. In February of this year, Hisun announced a $245 million JV with Pfizer, a project also devoted to branded generics. More details..... Stock Symbols: (SHA: 600267) (NSDQ: CLSN) (NYSE: PFE) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});